instruction:
Given a sentence, an entity and its sentiment towards the entity, verify if it is the correct sentiment towards the entity. Answer should be yes or no. Note that URLs in the text have been replaced with [Link].
question:
Verify if the sentiment of the following document towards the entity Lou Diamond Phillips is Negative . Cory says  Phillips ' blood alcohol level was .20 percent  which is more than twice the legal limit for driving.
answer:
no


question:
Verify if the sentiment of the following document towards the entity St. John is Positive . It is what this program needed  too  as much as anything. As the losses mounted  the helplessness did too. Nobody expected  Mullin âs return to  his  Utopia Parkway kingdom to be a magic elixir  but nobody figured on 0-11 in the Big East in Year 3  either. It has been hard for  Mullin âs guys  yes  but it has been just as hard for the faithful to keep their faith.
answer:
no


question:
Verify if the sentiment of the following document towards the entity David Mitchell is Positive . Zhang: As you know  Novartis disputes the $200 million figure because not all of that money went directly to CAR-T for cancer or toward the specific therapy behind Kymriah.  Mitchell : We're going to send you a clip from a blog post by Francis Collins  the head of the National Institutes of Health  in which  he  explains the long history of NIH in building the foundational science for CAR-T. Here's our position: From 1993 until 2017  NIH invested more than $200 million in the overall science of CAR-T. Even the seminal paper that was published in August of 2011 by Dr. Carl June of the University of Pennsylvania was funded in part by the NIH. All of the makers—Novartis  Kite (which will become Gilead)  and Juno [other companies pursuing CAR-T cell therapy]—are standing on that foundational science. The taxpayers invested early when the risk was the greatest. Zhang: What do you think is a fair price for Kymriah? Mitchell: Well  we have run the numbers a variety of different ways. Now  the point is no one knows the real numbers except Novartis  so we go back to the statements in a Reuters article in 2015 where Kite’s chief financial officer said they thought the base price was $150 000 for treatment  and analysts at that time were saying [costs could be] up to $300 000. When we tried to model  we can’t get over $300 000. Zhang: Novartis did take two unusual steps when announcing the price of Kymriah. First  they pointed to a British analysis to say they actually thought Kymriah was worth $600 000 to $750 000 but they were going to price it lower at $475 000. And second  they said patients who don’t respond after 30 days to the treatment will not have to pay.
answer:

yes